Avacta inks license agreement with Point Biopharma

By AuntMinnie.com staff writers

January 7, 2021 -- Avacta Group has signed a license agreement with Point Biopharma to provide that company with access to its pre/Cision technology for developing tumor-activated radiopharmaceuticals.

Point Biopharma develops radioligands for cancer treatment, and Avacta's pre/Cision technology can be used to modify radioligand-based drugs into tumor-activated "prodrugs," according to the firm. The license agreement will grant an exclusive license to Point Biopharma to use pre/Cision to develop these prodrugs and a nonexclusive license to use it to develop a range of fibroblast activation protein-activated radiopharmaceuticals, Avacta said.

Under terms of the deal, Point Biopharma will pay Avacta an upfront fee of $9.5 million, milestone payments of up to $8 million for each subsequent radiopharmaceutical prodrug developed, royalties on sales of fibroblast activation protein-activated radiopharmaceuticals, and a percentage of any sublicensing income Point Biopharma receives, according to the firm.


Copyright © 2021 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: